These substances are related to the DEA’s interest in researching hallucinogenic controlled products for clinical tests and research. The DEA asserts that it wants to support the regulated trials of schedule 1 substances, so increasing the production quota explains why this move is essential. The DEA also wants to research the requirements for manufacturing new drugs and the kind of impact marijuana has on the body. These steps are taken to work towards the Food and Drug Administration’s possibilities to approve a new drug.
Cannabis grower and edibles pioneer Maya Elisabeth makes the case that your sourdough starter is…
Berlin police are warning residents after receiving reports that suspected drug samples were being left…
Cannabis culture survived through decentralized human connection. Its future depends on whether the people building…
For years, the cannabis world has treated "the entourage effect" like settled science, a comforting…
After five years, two applications, six figures in expenses, and a maze of shifting rules,…
This article was originally published in 2023. From the hash and honey oil of the…